Perspective Therapeutics’ (CATX) “Outperform” Rating Reaffirmed at Wedbush

Wedbush reaffirmed their outperform rating on shares of Perspective Therapeutics (NYSEAMERICAN:CATX) in a report issued on Monday morning,Benzinga reports. They currently have a $11.00 price target on the stock.

A number of other research analysts have also commented on CATX. HC Wainwright upped their price target on Perspective Therapeutics from $12.00 to $13.00 and gave the stock a “buy” rating in a report on Monday, March 23rd. UBS Group upped their price target on Perspective Therapeutics from $7.00 to $8.00 and gave the stock a “buy” rating in a report on Wednesday, March 18th. Royal Bank Of Canada lowered their price objective on Perspective Therapeutics from $18.00 to $14.00 and set an “outperform” rating on the stock in a research report on Tuesday, March 17th. Truist Financial set a $12.00 price objective on Perspective Therapeutics in a research report on Tuesday, March 17th. Finally, Piper Sandler started coverage on Perspective Therapeutics in a research report on Thursday, February 19th. They set an “overweight” rating and a $16.00 price objective on the stock. One equities research analyst has rated the stock with a Strong Buy rating and eight have issued a Buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $12.63.

Perspective Therapeutics Price Performance

Shares of CATX stock opened at $4.55 on Monday. Perspective Therapeutics has a 12 month low of $1.86 and a 12 month high of $6.16. The stock has a 50 day moving average of $4.77 and a 200-day moving average of $3.59. The company has a current ratio of 5.17, a quick ratio of 5.17 and a debt-to-equity ratio of 0.01.

Perspective Therapeutics (NYSEAMERICAN:CATX) last issued its quarterly earnings results on Monday, March 16th. The company reported ($0.51) EPS for the quarter. Perspective Therapeutics had a negative return on equity of 41.79% and a negative net margin of 11,665.27%.The business had revenue of $0.04 million for the quarter. Research analysts predict that Perspective Therapeutics will post -1.17 EPS for the current year.

Institutional Trading of Perspective Therapeutics

A number of large investors have recently bought and sold shares of the stock. Vanguard Group Inc. grew its position in Perspective Therapeutics by 5.0% in the third quarter. Vanguard Group Inc. now owns 3,437,865 shares of the company’s stock valued at $11,792,000 after acquiring an additional 163,532 shares during the period. Avidity Partners Management LP grew its position in Perspective Therapeutics by 7.2% in the fourth quarter. Avidity Partners Management LP now owns 3,210,733 shares of the company’s stock valued at $8,830,000 after acquiring an additional 216,700 shares during the period. Geode Capital Management LLC grew its position in Perspective Therapeutics by 15.8% in the second quarter. Geode Capital Management LLC now owns 1,382,814 shares of the company’s stock valued at $4,758,000 after acquiring an additional 188,887 shares during the period. Opaleye Management Inc. bought a new stake in Perspective Therapeutics in the fourth quarter valued at $3,257,000. Finally, State Street Corp grew its position in Perspective Therapeutics by 3.3% in the fourth quarter. State Street Corp now owns 1,141,247 shares of the company’s stock valued at $3,138,000 after acquiring an additional 36,543 shares during the period. 54.66% of the stock is currently owned by institutional investors.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.